Earlier this year, Samsung Bioepis published the first in what is set to a be quarterly report on the US biosimilars market. Covering pricing data, uptake information and other topics relevant to the market – in the first report, interchangeability is in the spotlight – the report seeks to draw out market trends based on regularly-updated information across all biosimilar therapeutic categories.
Speaking to Generics Bulletin after the first report was published (see sidebar), Samsung Bioepis US head of market access Tom...